Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Physiomics, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK.
The project is expected to be completed during this calendar year and will focus on the analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours.
Dr Jim Millen, CEO said: 'We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity.'